WIN-027

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameWIN-027
Drug Alias NameQX027NQX-027-NWIN027WIN-027
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Thymic stromal lymphopoietinAnti-IL13
TargetsThymic stromal lymphopoietinInterleukin-13
Therapy Area/IndicationsDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWindward Bio Group AGLE2025 Therapeutics AGJiangsu Saifushi Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A